Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxPaths to a malaria vaccine illuminated by parasite genomicsTransition-state inhibitors of purine salvage and other prospective enzyme targets in malariaTissue signatures influence the activation of intrahepatic CD8(+) T cells against malaria sporozoitesMalaria vaccine can prevent millions of deaths in the worldStructural and Functional Basis for Inhibition of Erythrocyte Invasion by Antibodies that Target Plasmodium falciparum EBA-175Molecular basis of human cerebral malaria developmentDiscovery of a Plasmodium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase inhibitor (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reducesExpression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVATiming of pathogen adaptation to a multicomponent treatment.Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets.Malaria vaccine research and development: the role of the WHO MALVAC committeeHost-Parasite Interactions in Human Malaria: Clinical Implications of Basic ResearchImpact of regulated secretion on antiparasitic CD8 T cell responses.Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain.Plasmodium vivax antigen discovery based on alpha-helical coiled coil protein motifStrategies for designing and monitoring malaria vaccines targeting diverse antigensMicroneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route.Plasmodium vivax malaria vaccines: why are we where we are?Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureA nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malariaCombining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsA phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.The ETRAMP family member SEP2 is expressed throughout Plasmodium berghei life cycle and is released during sporozoite gliding motility.A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice.Protein microarray analysis of antibody responses to Plasmodium falciparum in western Kenyan highland sites with differing transmission levelsVaccines and global health.Synergistic and antagonistic interactions between bednets and vaccines in the control of malaria.Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate--Tackling the Cocktail ChallengePK4, a eukaryotic initiation factor 2α(eIF2α) kinase, is essential for the development of the erythrocytic cycle of Plasmodium.A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.Approaching the target: the path towards an effective malaria vaccine.Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.Recent advances in recombinant protein-based malaria vaccines.Application of a Scalable Plant Transient Gene Expression Platform for Malaria Vaccine Development.A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants.
P2860
Q24273364-D82AB990-B245-4CE5-BFC1-9379E36EB8B6Q26853267-DDD8CA79-15C0-4034-82C8-05277EC869DFQ27014881-F9864D8B-4D26-4FE2-8A59-8F7F98223E3DQ27026412-8844A8D9-885C-42E0-9287-D6ED7DA7F176Q27027430-2B97A509-139C-42C7-8678-A23BEADFB38FQ27678372-C81BA9EE-E410-47C8-9628-311F35D25910Q28066043-48CF2968-EBE6-41E4-96E2-CA3B7B75F273Q28271436-5E9B29D4-6C98-42AC-8FD3-D5BDC6AC7EAFQ28727937-16C4512C-2CC7-4038-B8A5-9DAEF7D45E3AQ31131957-D5B029E0-11F2-427A-A97D-B95FE3F14B52Q33590453-A986C110-FB4D-4CDC-A7CC-1A2DB1F2840CQ33611463-4FA03DBC-1903-4705-A6D8-D815CFD9F51CQ33701044-47974B1C-2369-43C3-A892-8016CCAD1AB9Q33756823-4416D1AA-6E1A-4260-86DD-E8D9D6C475B8Q33779750-E86FC33F-D322-4514-9925-F5CBC0195C01Q33800285-96AA755B-8D43-4E54-94BE-A9707CEB7B46Q33959038-DCC95EC5-3D0C-4A08-9A07-00D5356E6BADQ34072792-3FB2356F-1DC1-49BF-B0E3-F09AD27A5A7DQ34170071-5DE049E7-C943-4BF1-9E57-D16592CA186AQ34257253-37A0A582-7229-4493-AD8B-BC95AD56658BQ34469817-51BC86C8-247C-4277-82D4-635AE83AD778Q34600955-353B00E8-42FD-4CA7-B482-8C0B9F770F85Q34634002-0590CBC5-3734-4E5A-BC97-4F0DD0C1B2FBQ34734075-85778859-BDA1-4965-8FC9-3D2EEEAAB55AQ34806770-185AD667-1287-4C16-BB4B-7D0BEE2DB989Q34978590-5BC0339F-BD25-4998-8685-4E65831F4910Q35048518-19AC75E1-51AC-4C39-AD07-77913F029B44Q35061507-58F74CA2-F59C-4B1F-9277-9BB121547704Q35137116-0D62DFDA-A05D-488E-9518-B7FAA4D3C2B4Q35189926-2EF2097D-5B0F-4D5E-B3DD-541F873D07C9Q35683366-A9E808E4-8721-4EE8-AE6B-1B06EF36BB35Q35844920-FB7B244B-1F2D-403A-A1FB-D67DAE0F3160Q35887438-0978EC79-4C35-445A-ACB1-CEC7033C1391Q35924716-F917C79D-D430-4E5C-ABF9-9E82F4CD0175Q36043731-A694EE4D-586F-46F0-8760-2A705ACD7169Q36391845-AD8736D7-F972-4ED7-BEDF-B5AF7097988AQ36393102-7692785F-FDC6-4950-9708-38E639D86495Q36394182-FD305E8A-7F4D-4B89-96E7-519B2E64FBF2Q36396520-22FAD9AA-1984-4F0B-B540-FF26C6E00421Q36511421-F3D7E07A-23B3-4001-8EA0-3C2CFD1DD562
P2860
description
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
Scientific Article about Malaria in Biological Sciences Journal
@en
article scientifique (publié 2011/10/12)
@fr
articolo scientifico (pubblicato il 2011/10/12)
@it
artigo científico (publicado na 2011/10/12)
@pt
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
artículu científicu espublizáu en 2011
@ast
name
Vaccines against malaria
@ast
Vaccines against malaria
@en
Vaccines against malaria
@en-gb
Vaccines against malaria
@nl
type
label
Vaccines against malaria
@ast
Vaccines against malaria
@en
Vaccines against malaria
@en-gb
Vaccines against malaria
@nl
prefLabel
Vaccines against malaria
@ast
Vaccines against malaria
@en
Vaccines against malaria
@en-gb
Vaccines against malaria
@nl
P2860
P921
P3181
P356
P1476
Vaccines against malaria
@en
P2860
P304
P3181
P356
10.1098/RSTB.2011.0091
P407
P5008
P577
2011-10-12T00:00:00Z